Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement

NCT02462837 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped insufficient rate of accrual

Conditions

Urinary Bladder, Overactive
Pain
Lower Urinary Tract Symptoms

Interventions

DRUG: Mirabegron
DRUG: Placebo

Sponsor

Southern Illinois University

Collaborators

[object Object]
[object Object]